Navigation Links
New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Date:12/9/2010

sis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.  Afatinib is currently in phase III clinical development in NSCLC and breast cancer.  Apart from afatinib, Boehringer Ingelheim's late-stage oncology portfolio includes BIBF 1120, also in phase III development for the treatment of patients in two different tumor types, advanced NSCLC and ovarian cancer.  BIBF 1120 is an orally-administered investigational triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis:  fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).

In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the earlier stages of clinical development.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... , May 4, 2015  Geneia, a company ... technology solutions to improve healthcare efficiencies, today announced ... Rehabilitation Center (BNRC) use Geneia,s advanced analytics ... improve the quality and lower the cost of ... clinical, outcomes, claims and utilization data from multiple ...
Breaking Medicine Technology:Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:5/4/2015)... May 04, 2015 In a continuing ... for substance absue, Per Wickstrom, the founder of Choices ... Lounge and the “Salute to the Oscars” celebration ... on the top floor of the luxurious Beverly Hilton ... top producer of sustainable product placement in TV and ...
(Date:5/4/2015)... Each year, the Susan G. Komen organization ... awareness for breast cancer. This year, Dr. Mark Deutsch and ... the entertainment sponsor for the 25th annual Susan G. Komen ... the Lenox Square Mall. , The Komen organization hopes have ... $1.2 million. Perimeter Plastic Surgery has not only taken on ...
(Date:5/4/2015)... “ LiveSchool ” was featured on NewsWatch ... look at the latest and coolest applications on the ... host of AppWatch and technology expert, conducted the app ... teachers to reward students with good behavior. , Positive ... the classroom. And the good people at LiveSchool ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis is ... of senior citizens (1) and 27 million Obamacare-insured Americans ... system. Additionally, as older healthcare employees retire, there will ... U.S. Census Bureau, the number of American workers 65 ... while those 25 to 54 will likely increase 2%. ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... NASHVILLE, Tenn., Sept. 17 Approximately 100 student,government ... nationwide, will meet in Nashville Oct. 5-7 to ... new non-profit group,created to engage young Americans in ... convene at the Scarritt-Bennett Center, just blocks from,the ...
... Sept. 17 AAHSA President & CEO,Larry Minnix, president ... for the Aging (AAHSA) joined AAHSA board members Jill ... Gould, CEO of,Volunteers of America (VOA) on the NonProfit ... published annually, features executives and thought leaders,who are selected ...
... AMN Healthcare, the largest,healthcare staffing company in the ... (OGPI), today announced AMN,s,endorsement of a Code of ... United States., A task force, including AMN ... licensure bodies developed the "Voluntary,Code of Ethical Conduct ...
... Foundation makes $18 million investment in recess to ... low-income schools., PRINCETON, N.J., Sept. 17 The ... announced a,major investment to bring safe and healthy playtime ... reach that goal, the Foundation is teaming up,with Sports4Kids, ...
... School of Medicine have modified a honeybee venom toxin so ... the inner workings of ion channels that control heart rate ... channels selectively allow the passage of small ions such as ... , The study, published in the Proceedings of the ...
... and Outlines Ways to Effectively Address New and Emerging Threats ... ... Scottsdale, Ariz (PRWEB) September 17, 2008 -- With ... of mobile technology, growth in vulnerable applications, operation systems and ...
Cached Medicine News:Health News:College Students Seek Healthcare Solutions on Eve of Debate 2Health News:Three AAHSA Leaders Named to NonProfit Times' 'Power and Influence Top 50' List 2Health News:AMN Healthcare, OGPI Endorse AcademyHealth's Code of Conduct for Recruitment of Foreign-Educated Nurses 2Health News:AMN Healthcare, OGPI Endorse AcademyHealth's Code of Conduct for Recruitment of Foreign-Educated Nurses 3Health News:Tag, You're Healthy! 2Health News:Penn researchers use honeybee venom toxin to develop a new tool for studying hypertension 2Health News:Lumension Security To Host Industry Webinar On Staying Ahead Of Threats 2Health News:Lumension Security To Host Industry Webinar On Staying Ahead Of Threats 3Health News:Lumension Security To Host Industry Webinar On Staying Ahead Of Threats 4
400 Series Monopolar Foot Activated Forceps...
Dissecting Forceps, straight, with RF-cable, 7" (18 cm). For use with all electrosurgical generators with standard three-prong sockets....
Extended blade - 25/box....
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
Medicine Products: